405 related articles for article (PubMed ID: 18483648)
21. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.
Jakob C; Sterz J; Liebisch P; Mieth M; Rademacher J; Goerke A; Heider U; Fleissner C; Kaiser M; von Metzler I; Müller C; Sezer O
Leukemia; 2008 Sep; 22(9):1767-72. PubMed ID: 18580957
[TBL] [Abstract][Full Text] [Related]
22. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma.
Kyrtsonis MC; Maltezas D; Tzenou T; Koulieris E; Bradwell AR
Semin Hematol; 2009 Apr; 46(2):110-7. PubMed ID: 19389494
[TBL] [Abstract][Full Text] [Related]
23. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
[TBL] [Abstract][Full Text] [Related]
24. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of stratification systems in multiple myeloma. II. Clinical staging systems.
Scudla V; Indrák K
Neoplasma; 1985; 32(4):481-93. PubMed ID: 4047259
[TBL] [Abstract][Full Text] [Related]
26. Analysis of criteria in staging in multiple myeloma.
Pennec Y; Mottier D; Youinou P; Asselain B; Miossec P; Le Goff P; Le Prise PY; Le Menn G
Haematologia (Budap); 1982; 15(2):221-6. PubMed ID: 7160667
[TBL] [Abstract][Full Text] [Related]
27. DNA-image cytometry and clinical staging systems in multiple myeloma.
Kropff M; Leo E; Steinfurth G; Esselborn H; Adler CP; Böcking A
Anticancer Res; 1994; 14(5B):2183-8. PubMed ID: 7840520
[TBL] [Abstract][Full Text] [Related]
28. A comparison of two staging systems for myeloma.
Vercelli D; Cozzolino F; Di Guglielmo R
Nouv Rev Fr Hematol (1978); 1981; 23(2):107-10. PubMed ID: 7290984
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors and therapeutic results in multiple myeloma.
Nagai M; Kitahara T; Minato K; Takenaka T; Konda C; Seki S; Shimoyama M
Jpn J Clin Oncol; 1985 Sep; 15(3):505-15. PubMed ID: 4057632
[TBL] [Abstract][Full Text] [Related]
30. [Clinical features of multiple myeloma patients with extramedullary disease: a report of 40 cases from a single center].
Chen HF; Fu WJ; Wang DX; Yuan ZG; Chen YB; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):655-8. PubMed ID: 18399168
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
Pasqualetti P; Collacciani A; Maccarone C; Casale R
Biomed Pharmacother; 1996; 50(1):29-35. PubMed ID: 8672729
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic evaluation in multiple myeloma. Relationship between immunological types, single prognostic factors, clinical staging systems, morphological classification systems and survival].
Pasqualetti P; Colantonio D; Casale R; Di Lauro G; Collacciani A; Festuccia V; Trotta A; Natali G
Ann Ital Med Int; 1990; 5(3 Pt 1):195-204. PubMed ID: 2288822
[TBL] [Abstract][Full Text] [Related]
33. [Evaluation of a morphologic staging method (myeloma progression score) in multiple myeloma].
Pasqualetti P; Casale R; Collacciani A; Colantonio D
Medicina (Firenze); 1989; 9(3):280-2. PubMed ID: 2615598
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic factors in multiple myeloma. Selection using multivariate analysis].
Pasqualetti P; Colantonio D; Casale R; Lorenzetti G; Natali G
Recenti Prog Med; 1989 Oct; 80(10):543-6. PubMed ID: 2602637
[TBL] [Abstract][Full Text] [Related]
35. IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients.
Shimamoto Y
Cancer Detect Prev; 1995; 19(5):426-35. PubMed ID: 7585729
[TBL] [Abstract][Full Text] [Related]
36. [Expression and clinical significance of beta-catenin in multiple myeloma].
Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
[TBL] [Abstract][Full Text] [Related]
37. Factors affecting outcome of patients with multiple myeloma.
Basit A; Siddiqui N; Hameed A; Muzaffar N; Athar S
J Ayub Med Coll Abbottabad; 2014; 26(3):376-9. PubMed ID: 25671952
[TBL] [Abstract][Full Text] [Related]
38. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system.
Durie BG
Eur J Cancer; 2006 Jul; 42(11):1539-43. PubMed ID: 16777405
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
[TBL] [Abstract][Full Text] [Related]
40. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma.
Katodritou E; Verrou E; Hadjiaggelidou C; Gastari V; Laschos K; Kontovinis L; Kapetanos D; Constantinou N; Terpos E; Zervas K
Am J Hematol; 2008 Sep; 83(9):697-701. PubMed ID: 18626886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
